Skip to main content

Table 2 Patient Response Evaluation

From: Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma

 

All (N = 54)

Group 1 (N = 13)

Group 2 (N = 31)

Group 3 (N = 10)

TTP (days)

 Naïve B-cell

44

71

35

 Naïve T-cell

31

31

32.5

 Relapsed B-cell

24

19

23

85

 Relapsed T-cell

43

43

73

24

Objective Response (n)

 Naïve B-cell

8

4

4

 Naïve T-cell

5

1

4

 Relapsed B-cell

4

1

1

2

 Relapsed T-cell

4

1

2

1